Literature DB >> 8140892

Herpes simplex virus type 1 strain KOS-63 does not cause acute or recurrent ocular disease and does not reactivate ganglionic latency in vivo.

W G Stroop1, M C Banks.   

Abstract

The virological, clinical, and histopathological manifestations of acute and experimentally reactivated infections of eyes and trigeminal ganglia have been studied following intranasal infection of rabbits with herpes simplex virus type 1 (strain KOS-63). All animals shed virus in nasal secretions, but only three shed virus in tear film during the first 12 days of infection. No animal developed clinical or histological evidence of corneal or retinal ocular disease at any time after infection. KOS-63 established trigeminal ganglionic latency; viral RNA, restricted to neuronal nuclei, was detected by in situ hybridization, and virus was recovered from co-cultivation cultures of nervous tissue, but not from cell-free homogenates. Reactivation of latent trigeminal ganglionic infection was attempted by intravenous administration of cyclophosphamide, followed by dexamethasone 24 h later. Injection of the drugs failed to reactivate KOS-63 latency; no animal shed virus in nasal or ocular secretions, and no animal developed gross or microscopic corneal lesions. In addition, viral antigens were not detected by immunofluorescence microscopy in ganglia from rabbits subjected to the drug protocol, and virus was only recovered from ganglia by in vitro co-cultivation reactivation techniques. The failure of KOS-63 to reactivate was not due to an inherent failure of populate and infect the ganglion, because the virus did not reactivate from ganglia that contained many latently infected cells. These studies demonstrate that, although KOS-63 is neuroinvasive and capable of establishing latency, it is virtually nonvirulent for the eye, and cannot be reactivated by a systemic immunosuppressive trigger known to reactivate other HSV-1 strains.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8140892     DOI: 10.1007/bf00386250

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  39 in total

1.  Herpes simplex virus stromal keratitis is not titer-dependent and does not correlate with neurovirulence.

Authors:  D R Grau; R J Visalli; C R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  1989-12       Impact factor: 4.799

Review 2.  Herpes simplex virus encephalitis of the human adult: reactivation of latent brain infection.

Authors:  W G Stroop
Journal:  Pathol Immunopathol Res       Date:  1986

3.  Strain specificity of spontaneous and adrenergically induced HSV-1 ocular reactivation in latently infected rabbits.

Authors:  J M Hill; M A Rayfield; Y Haruta
Journal:  Curr Eye Res       Date:  1987-01       Impact factor: 2.424

4.  A herpes simplex virus type 1 variant, deleted in the promoter region of the latency-associated transcripts, does not produce any detectable minor RNA species during latency in the mouse trigeminal ganglion.

Authors:  W J Mitchell; I Steiner; S M Brown; A R MacLean; J H Subak-Sharpe; N W Fraser
Journal:  J Gen Virol       Date:  1990-04       Impact factor: 3.891

5.  The herpes simplex virus latency-associated transcript is spliced during the latent phase of infection.

Authors:  E K Wagner; W M Flanagan; G Devi-Rao; Y F Zhang; J M Hill; K P Anderson; J G Stevens
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

6.  Strain specificity of clinical isolates of herpes simplex virus.

Authors:  A H Wander; Y M Centifanto; H E Kaufman
Journal:  Arch Ophthalmol       Date:  1980-08

7.  HSV-1 shedding by lontophoresis of 6-hydroxydopamine followed by topical epinephrine.

Authors:  Y Shimomura; L P Gangarosa; M Kataoka; J M Hill
Journal:  Invest Ophthalmol Vis Sci       Date:  1983-12       Impact factor: 4.799

8.  Corneal nerves are necessary for adrenergic reactivation of ocular herpes.

Authors:  D S Rootman; Y Haruta; J M Hill; H E Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  1988-03       Impact factor: 4.799

9.  Antibody activity to herpes simplex virus in mouse Ig classes and IgG subclasses.

Authors:  R R McKendall; W Woo
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

10.  Biological characterization of a herpes simplex virus intertypic recombinant which is completely and specifically non-neurovirulent.

Authors:  R L Thompson; J G Stevens
Journal:  Virology       Date:  1983-11       Impact factor: 3.616

View more
  6 in total

1.  The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation.

Authors:  N M Sawtell; D K Poon; C S Tansky; R L Thompson
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

2.  Herpes simplex virus type 1 latency-associated transcript gene promotes neuronal survival.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits.

Authors:  A B Nesburn; S Slanina; R L Burke; H Ghiasi; S Bahri; S L Wechsler
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  A primary neuron culture system for the study of herpes simplex virus latency and reactivation.

Authors:  Mariko Kobayashi; Ju-Youn Kim; Vladimir Camarena; Pamela C Roehm; Moses V Chao; Angus C Wilson; Ian Mohr
Journal:  J Vis Exp       Date:  2012-04-02       Impact factor: 1.355

5.  Cloning and restriction endonuclease mapping of herpes simplex virus type-1 strains H129 and +GC.

Authors:  T E Kienzle; J S Henkel; J Y Ling; M C Banks; D R Beers; B Jones; W G Stroop
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

6.  Herpes simplex virus-1 KOS-63 strain is virulent and causes titer-dependent corneal nerve damage and keratitis.

Authors:  Hamid-Reza Moein; Victor G Sendra; Arsia Jamali; Ahmad Kheirkhah; Deshea L Harris; Pedram Hamrah
Journal:  Sci Rep       Date:  2021-02-19       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.